Eli Lilly to join lawsuit over GLP-1 shortage
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,
Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know
Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .
The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the ...
Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...
Macupatide (LY-3532226) is under development for the treatment of type 2 diabetes, obesity and type 1 diabetes mellitus. It is administered through subcutaneous route. It is a long acting new ...
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback